[Would prescription of erythropoiesis-stimulating agents in pre-dialysis change after results from TREAT study?].
Alcázar
R
R
Servicios de Nefrología, Hospital Infanta Leonor, Spain.
Tato
A
A
García
F
F
Barrios
V
V
Quereda
C
C
D000368:Aged; D000740:Anemia / Q000150:complications* / Q000188:drug therapy*; D002908:Chronic Disease; D000068256:Darbepoetin alfa; D004311:Double-Blind Method; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications*; D008297:Male; D006435:Renal Dialysis
D006397:Hematinics; D004921:Erythropoietin; D000068256:Darbepoetin alfa